LT3902547T - Csf1r inhibitoriai, skirti panaudoti vėžio gydymui - Google Patents
Csf1r inhibitoriai, skirti panaudoti vėžio gydymuiInfo
- Publication number
- LT3902547T LT3902547T LTEPPCT/US2019/068311T LTUS2019068311T LT3902547T LT 3902547 T LT3902547 T LT 3902547T LT US2019068311 T LTUS2019068311 T LT US2019068311T LT 3902547 T LT3902547 T LT 3902547T
- Authority
- LT
- Lithuania
- Prior art keywords
- treating cancer
- csf1r inhibitors
- csf1r
- inhibitors
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7153—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons or colony-stimulating factors [CSF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862786105P | 2018-12-28 | 2018-12-28 | |
| US201962926341P | 2019-10-25 | 2019-10-25 | |
| US201962933830P | 2019-11-11 | 2019-11-11 | |
| PCT/US2019/068311 WO2020139828A1 (en) | 2018-12-28 | 2019-12-23 | Csf1r inhibitors for use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3902547T true LT3902547T (lt) | 2024-01-25 |
Family
ID=69191281
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2019/068311T LT3902547T (lt) | 2018-12-28 | 2019-12-23 | Csf1r inhibitoriai, skirti panaudoti vėžio gydymui |
| LTEP23195809.1T LT4303583T (lt) | 2018-12-28 | 2019-12-23 | Csf1r inhibitoriai, skirti panaudoti gydant tenosinovinius gigantinių ląstelių navikus |
| LTPA2026508C LTPA2026508I1 (https=) | 2018-12-28 | 2026-03-03 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP23195809.1T LT4303583T (lt) | 2018-12-28 | 2019-12-23 | Csf1r inhibitoriai, skirti panaudoti gydant tenosinovinius gigantinių ląstelių navikus |
| LTPA2026508C LTPA2026508I1 (https=) | 2018-12-28 | 2026-03-03 |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US11103507B2 (https=) |
| EP (3) | EP3902547B1 (https=) |
| JP (2) | JP7626702B2 (https=) |
| KR (1) | KR20210119411A (https=) |
| CN (4) | CN118453609A (https=) |
| AU (3) | AU2019416117B2 (https=) |
| BR (1) | BR112021012812A2 (https=) |
| CA (1) | CA3124112A1 (https=) |
| DK (2) | DK3902547T3 (https=) |
| ES (2) | ES3049362T3 (https=) |
| FI (3) | FI3902547T3 (https=) |
| HR (2) | HRP20231478T1 (https=) |
| HU (2) | HUE065492T2 (https=) |
| IL (2) | IL284199B1 (https=) |
| LT (3) | LT3902547T (https=) |
| MX (2) | MX2021007927A (https=) |
| NO (1) | NO2026009I1 (https=) |
| PL (2) | PL3902547T3 (https=) |
| PT (2) | PT3902547T (https=) |
| RS (2) | RS64993B1 (https=) |
| SG (1) | SG11202105747XA (https=) |
| SI (2) | SI3902547T1 (https=) |
| SM (2) | SMT202500389T1 (https=) |
| TW (2) | TWI873113B (https=) |
| WO (1) | WO2020139828A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118416236A (zh) | 2018-01-31 | 2024-08-02 | 德西费拉制药有限责任公司 | 治疗胃肠道间质瘤的组合疗法 |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| BR112021012812A2 (pt) * | 2018-12-28 | 2021-12-07 | Deciphera Pharmaceuticals Llc | Csf1r inhibitors para uso e tratamento de câncer |
| WO2020185812A1 (en) | 2019-03-11 | 2020-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of ripretinib |
| US11518758B2 (en) | 2019-05-10 | 2022-12-06 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| PE20220597A1 (es) | 2019-05-10 | 2022-04-22 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos |
| PE20221083A1 (es) | 2019-06-17 | 2022-07-05 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso |
| EP4013412B1 (en) | 2019-08-12 | 2026-01-28 | Deciphera Pharmaceuticals, LLC | Ripretinib for treating gastrointestinal stromal tumors |
| TWI878335B (zh) | 2019-08-12 | 2025-04-01 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| EP4084779B1 (en) | 2019-12-30 | 2024-10-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| MX2022008103A (es) | 2019-12-30 | 2022-09-19 | Deciphera Pharmaceuticals Llc | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. |
| US20230382871A1 (en) * | 2020-09-23 | 2023-11-30 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Csf1r kinase inhibitor and use thereof |
| IL302807A (en) | 2020-11-18 | 2023-07-01 | Deciphera Pharmaceuticals Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
| CN113880812A (zh) * | 2021-11-17 | 2022-01-04 | 上海皓元生物医药科技有限公司 | 一种csf-ir抑制剂的制备方法 |
| PE20250609A1 (es) | 2021-12-03 | 2025-02-26 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos |
| CA3240263A1 (en) | 2021-12-09 | 2023-06-15 | Daniel L. Flynn | Raf kinase inhibitors and methods of use thereof |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
| US20260085124A1 (en) * | 2022-09-12 | 2026-03-26 | AmMax Bio, Inc. | Treatment of tenosynovial giant cell tumor |
| EP4483866A1 (en) | 2023-06-28 | 2025-01-01 | Makrolife Biotech GmbH | Pharmaceutical compositions for the treatment or prevention of cancer |
| AU2024372404A1 (en) * | 2023-10-29 | 2026-04-16 | Deciphera Pharmaceuticals, Llc | Methods of treating tenosynovial giant cell tumors |
| CN117624132B (zh) * | 2023-11-28 | 2026-04-21 | 上海相辉医药科技有限公司 | 一种CSF-1R激酶抑制剂Vimseltinib(DCC-3014)的制备方法 |
| WO2025122952A1 (en) * | 2023-12-08 | 2025-06-12 | Deciphera Pharmaceuticals, Llc | Formulations of vimseltinib |
| US20250206720A1 (en) | 2023-12-08 | 2025-06-26 | Deciphera Pharmaceuticals, Llc | Solid forms of an ulk inhibitor |
| WO2025231106A1 (en) * | 2024-05-01 | 2025-11-06 | Deciphera Pharmaceuticals, Llc | Csf-1r inhibitors and methods of use thereof |
| CN118593504B (zh) * | 2024-06-03 | 2025-03-18 | 北京大学第三医院（北京大学第三临床医学院） | 氘可来昔替尼或其盐在制备pvns药物方面的新用途 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5794047A (en) | 1980-12-01 | 1982-06-11 | Ricoh Co Ltd | Novel disazo compound and preparation of the same |
| BR0209774A (pt) | 2001-05-29 | 2004-06-01 | Schering Ag | Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento |
| AU2002313249B2 (en) | 2001-06-22 | 2008-08-21 | Kirin Pharma Kabushiki Kaisha | Quinoline derivative and quinazoline derivate inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
| WO2006136837A2 (en) | 2005-06-23 | 2006-12-28 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
| CA2649288C (en) | 2006-04-19 | 2015-11-24 | Novartis Ag | 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| US8188113B2 (en) | 2006-09-14 | 2012-05-29 | Deciphera Pharmaceuticals, Inc. | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| WO2008046216A1 (en) | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
| AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| WO2008131276A1 (en) | 2007-04-20 | 2008-10-30 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| WO2009108670A1 (en) | 2008-02-28 | 2009-09-03 | Merck Serono S.A. | Protein kinase inhibitors and use thereof |
| JP5444365B2 (ja) | 2008-10-29 | 2014-03-19 | デシフェラ ファーマシューティカルズ，エルエルシー | 抗癌活性および抗増殖活性を示すシクロプロパンアミドおよび類似物質 |
| SG185073A1 (en) | 2010-04-29 | 2012-12-28 | Deciphera Pharmaceuticals Llc | Cyclopropyl dicarboxamides and analogs exhibiting anti-cancer and anti-proliferative activites |
| CA2800998A1 (en) | 2010-04-29 | 2011-11-10 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| JP2015507606A (ja) | 2011-11-22 | 2015-03-12 | デシフェラ ファーマシューティカルズ，エルエルシー | 抗癌および抗増殖作用を示すピリドンアミドおよび類似体 |
| WO2013134298A1 (en) | 2012-03-07 | 2013-09-12 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| US9758258B2 (en) | 2012-11-29 | 2017-09-12 | Sirkorsky Aircraft Corporation | Rotary wing aircraft blade tracking |
| WO2014145023A1 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
| DK2968286T3 (en) * | 2013-03-15 | 2018-01-02 | Deciphera Pharmaceuticals Llc | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS THAT HAVE ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES |
| WO2014145015A2 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities |
| WO2014145029A2 (en) | 2013-03-15 | 2014-09-18 | Deciphera Pharmaceuticals, Llc | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
| US9012635B2 (en) | 2013-03-15 | 2015-04-21 | Deciphera Pharmaceuticals, Llc | Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| JP6364472B2 (ja) | 2013-03-15 | 2018-07-25 | デシフェラ ファーマシューティカルズ，エルエルシー | 抗がんおよび抗増殖活性を示すｎ−アシル−ｎ’−（ピリジン−２−イル）尿素および類似体 |
| AR097584A1 (es) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| WO2018160917A1 (en) | 2017-03-03 | 2018-09-07 | Janssen Biotech, Inc. | Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer |
| EP3632906B1 (en) | 2017-05-24 | 2023-12-13 | Abbisko Therapeutics Co., Ltd. | Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy |
| EP3632907B1 (en) | 2017-05-24 | 2024-02-28 | Abbisko Therapeutics Co., Ltd. | N-(azaaryl)cyclolactam-1-carboxamide derivative, preparation method therefor, and use thereof |
| MY205552A (en) | 2017-05-30 | 2024-10-25 | Deciphera Pharmaceuticals Inc | Use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl ]-3-phenylurea and analogs for the treatment of cancers associated with genetic abnormalities in platelet derived growth factor receptor alpha |
| MY202326A (en) | 2017-09-14 | 2024-04-24 | Daiichi Sankyo Co Ltd | Compound having cyclic structure |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| BR112021012812A2 (pt) * | 2018-12-28 | 2021-12-07 | Deciphera Pharmaceuticals Llc | Csf1r inhibitors para uso e tratamento de câncer |
| US11518758B2 (en) | 2019-05-10 | 2022-12-06 | Deciphera Pharmaceuticals, Llc | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| PE20220597A1 (es) | 2019-05-10 | 2022-04-22 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos |
| TWI912522B (zh) | 2021-05-24 | 2026-01-21 | 大陸商上海和譽生物醫藥科技有限公司 | 一種結晶型csf-1r抑制劑酸式鹽及其製備方法和應用 |
| CN113880812A (zh) | 2021-11-17 | 2022-01-04 | 上海皓元生物医药科技有限公司 | 一种csf-ir抑制剂的制备方法 |
| CN116283919A (zh) | 2023-03-21 | 2023-06-23 | 上海皓元医药股份有限公司 | Vimseltinib的新晶型及其制备方法 |
-
2019
- 2019-12-23 BR BR112021012812A patent/BR112021012812A2/pt unknown
- 2019-12-23 PL PL19842712.2T patent/PL3902547T3/pl unknown
- 2019-12-23 EP EP19842712.2A patent/EP3902547B1/en active Active
- 2019-12-23 US US16/725,282 patent/US11103507B2/en active Active
- 2019-12-23 CN CN202410608820.2A patent/CN118453609A/zh active Pending
- 2019-12-23 SI SI201930651T patent/SI3902547T1/sl unknown
- 2019-12-23 PL PL23195809.1T patent/PL4303583T3/pl unknown
- 2019-12-23 DK DK19842712.2T patent/DK3902547T3/da active
- 2019-12-23 KR KR1020217024011A patent/KR20210119411A/ko not_active Ceased
- 2019-12-23 SM SM20250389T patent/SMT202500389T1/it unknown
- 2019-12-23 RS RS20231149A patent/RS64993B1/sr unknown
- 2019-12-23 ES ES23195809T patent/ES3049362T3/es active Active
- 2019-12-23 CN CN202410608828.9A patent/CN118453610A/zh active Pending
- 2019-12-23 ES ES19842712T patent/ES2964489T3/es active Active
- 2019-12-23 HR HRP20231478TT patent/HRP20231478T1/hr unknown
- 2019-12-23 EP EP25190979.2A patent/EP4647767A3/en active Pending
- 2019-12-23 HR HRP20251261TT patent/HRP20251261T1/hr unknown
- 2019-12-23 RS RS20251011A patent/RS67303B1/sr unknown
- 2019-12-23 JP JP2021537759A patent/JP7626702B2/ja active Active
- 2019-12-23 SM SM20230468T patent/SMT202300468T1/it unknown
- 2019-12-23 HU HUE19842712A patent/HUE065492T2/hu unknown
- 2019-12-23 PT PT198427122T patent/PT3902547T/pt unknown
- 2019-12-23 LT LTEPPCT/US2019/068311T patent/LT3902547T/lt unknown
- 2019-12-23 CA CA3124112A patent/CA3124112A1/en active Pending
- 2019-12-23 WO PCT/US2019/068311 patent/WO2020139828A1/en not_active Ceased
- 2019-12-23 HU HUE23195809A patent/HUE073437T2/hu unknown
- 2019-12-23 FI FIEP19842712.2T patent/FI3902547T3/fi active
- 2019-12-23 CN CN201980092790.1A patent/CN113453684B/zh active Active
- 2019-12-23 SI SI201930977T patent/SI4303583T1/sl unknown
- 2019-12-23 CN CN202410608814.7A patent/CN118453608A/zh active Pending
- 2019-12-23 PT PT231958091T patent/PT4303583T/pt unknown
- 2019-12-23 MX MX2021007927A patent/MX2021007927A/es unknown
- 2019-12-23 DK DK23195809.1T patent/DK4303583T3/da active
- 2019-12-23 EP EP23195809.1A patent/EP4303583B1/en active Active
- 2019-12-23 AU AU2019416117A patent/AU2019416117B2/en active Active
- 2019-12-23 LT LTEP23195809.1T patent/LT4303583T/lt unknown
- 2019-12-23 FI FIEP23195809.1T patent/FI4303583T3/fi active
- 2019-12-23 SG SG11202105747XA patent/SG11202105747XA/en unknown
- 2019-12-27 TW TW108148219A patent/TWI873113B/zh active
- 2019-12-27 TW TW114101930A patent/TW202541807A/zh unknown
-
2021
- 2021-06-20 IL IL284199A patent/IL284199B1/en unknown
- 2021-06-25 US US17/358,137 patent/US11679110B2/en active Active
- 2021-06-28 MX MX2024002838A patent/MX2024002838A/es unknown
-
2023
- 2023-04-28 US US18/140,942 patent/US12285430B2/en active Active
-
2024
- 2024-07-22 AU AU2024205010A patent/AU2024205010B2/en active Active
-
2025
- 2025-01-23 JP JP2025009594A patent/JP2025066790A/ja active Pending
- 2025-03-14 US US19/079,727 patent/US12485120B2/en active Active
- 2025-10-21 US US19/364,654 patent/US12582655B2/en active Active
- 2025-12-18 IL IL325448A patent/IL325448A/en unknown
-
2026
- 2026-01-30 AU AU2026200677A patent/AU2026200677A1/en active Pending
- 2026-03-03 LT LTPA2026508C patent/LTPA2026508I1/lt unknown
- 2026-03-03 NO NO2026009C patent/NO2026009I1/no unknown
- 2026-03-05 FI FIC20260007C patent/FIC20260007I1/fi unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202105747XA (en) | Csf1r inhibitors for use in treating cancer | |
| SG11202104356VA (en) | Bt1718 for use in treating cancer | |
| IL268430A (en) | Methods for treating cancer using hsp90 inhibitors | |
| IL280158A (en) | Methods of treating cancer with the PI3K inhibitor, GDC-0077 | |
| SG10201913331VA (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| IL272088A (en) | A DHODH inhibitor for use in the treatment of hematological cancer | |
| SI3806898T1 (sl) | Antagonist Gremlin-1 za uporabo pri zdravljenju raka | |
| ZA202007955B (en) | Ccr5 inhibitor for use in treating cancer | |
| SMT202100207T1 (it) | Inibitori della farnesiltransferasi per il trattamento del cancro | |
| GB201702160D0 (en) | Inhibitors for use in therapy | |
| PT3293201T (pt) | Combinação de adenovírus e inibidores de ponto de verificação para tratamento do cancro | |
| IL280830A (en) | Bracelets for use in cancer treatment methods | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| IL285538A (en) | Combined therapies for use in cancer treatment | |
| GB201709417D0 (en) | Cyclin dependent kinase 4/6 inhibitors for use in methods of treating cancer | |
| GB201709076D0 (en) | Parp inhibitors for use in methods of treating cancer | |
| PT3813832T (pt) | Compostos para utilização na prevenção ou tratamento de cancro | |
| HK40060258A (zh) | 用於治疗癌症的bt1718 | |
| GB2578008B (en) | 1-Acetyl-5-Nitro-4-Phenyl-3-Pyrrolin-2-one for use in cancer treatment | |
| HK40052012A (en) | Usp19 inhibitors for use in therapy | |
| HK40031759A (en) | Dhodh inhibitor for use in treating hematologic cancers |